Kyverna Therapeutics, Inc. (KYTX)
7.66
-0.19
(-2.42%)
USD |
NASDAQ |
Jun 10, 16:00
7.645
-0.02
(-0.20%)
After-Hours: 20:00
Kyverna Therapeutics Total Liabilities (Quarterly) : 61.44M for March 31, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 61.44M |
| December 31, 2025 | 62.68M |
| September 30, 2025 | 35.21M |
| June 30, 2025 | 42.13M |
| March 31, 2025 | 36.64M |
| December 31, 2024 | 39.93M |
| September 30, 2024 | 36.49M |
| Date | Value |
|---|---|
| June 30, 2024 | 29.61M |
| March 31, 2024 | 28.99M |
| December 31, 2023 | 26.02M |
| September 30, 2023 | |
| June 30, 2023 | |
| March 31, 2023 | |
| December 31, 2022 | 20.25M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| X4 Pharmaceuticals, Inc. | 101.83M |
| Arrowhead Pharmaceuticals, Inc. | 1.669B |
| Oncolytics Biotech, Inc. | 13.29M |
| Sangamo Therapeutics, Inc. | 78.92M |
| Sarepta Therapeutics, Inc. | 1.674B |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 257.02M |
| Shareholders Equity (Quarterly) | 195.58M |
| Debt to Equity Ratio | 0.1726 |
| Current Ratio | 8.146 |
| Net Debt Paydown Yield | -0.98% |